David B Miklos

List of Publications by Year
in descending order

151 papers	13,789 citations	71102 41 h-index	22166 113 g-index
151 all docs	151 docs citations	151 times ranked	11345 citing authors

#	Article	IF	Citations
1	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. New England Journal of Medicine, 2017, 377, 2531-2544.	27.0	3,865
2	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€“2 trial. Lancet Oncology, The, 2019, 20, 31-42.	10.7	1,467
3	KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. New England Journal of Medicine, 2020, 382, 1331-1342.	27.0	1,067
4	Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. New England Journal of Medicine, 2022, 386, 640-654.	27.0	586
5	Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. Journal of Clinical Oncology, 2020, 38, 3119-3128.	1.6	481
6	Rituximab for steroid-refractory chronic graft-versus-host disease. Blood, 2006, 108, 756-762.	1.4	422
7	Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing. Science Translational Medicine, 2009, 1, 12ra23.	12.4	372
8	Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood, 2005, 105, 2973-2978.	1.4	361
9	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood, 2017, 130, 2243-2250.	1.4	352
10	The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2017, 23, 211-234.	2.0	328
11	CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nature Medicine, 2021, 27, 1419-1431.	30.7	273
12	Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood, 2015, 125, 3679-3687.	1.4	270
13	Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances, 2020, 4, 4898-4911.	5.2	238
14	Minor Histocompatibility Antigen DBY Elicits a Coordinated B and T Cell Response after Allogeneic Stem Cell Transplantation. Journal of Experimental Medicine, 2004, 199, 1133-1142.	8.5	162
15	High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 21194-21199.	7.1	160
16	TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors. Blood, 2009, 114, 1099-1109.	1.4	150
17	Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood, 2004, 103, 353-359.	1.4	149
18	Toward Biomarkers for Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group Report. Biology of Blood and Marrow Transplantation, 2006, 12, 126-137.	2.0	139

#	Article	IF	Citations
19	Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2305-2321.	2.0	132
20	Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival. Biology of Blood and Marrow Transplantation, 2014, 20, 1307-1313.	2.0	124
21	Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-Î² production. Blood, 2017, 129, 2570-2580.	1.4	122
22	Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence. Blood, 2012, 119, 6145-6154.	1.4	107
23	Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and â€œantibodyomeâ€•measures. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4148-4153.	7.1	98
24	Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma. Blood Advances, 2021, 5, 143-155.	5.2	92
25	Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood, 2020, 135, 2106-2109.	1.4	90
26	H-Y Antibody Development Associates With Acute Rejection in Female Patients With Male Kidney Transplants. Transplantation, 2008, 86, 75-81.	1.0	84
27	CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel. Blood, 2021, 138, 1081-1085.	1.4	84
28	Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. Journal of Clinical Oncology, 2023, 41, 555-567.	1.6	82
29	Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience. Blood, 2018, 132, 91-91.	1.4	81
30	Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial. Journal of Clinical Oncology, 2021, 39, 3034-3043.	1.6	76
31	Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood, 2016, 128, 2899-2908.	1.4	70
32	A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. Clinical Cancer Research, 2016, 22, 319-327.	7.0	68
33	CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cellâ€“Associated Neurotoxicity. Cancer Discovery, 2017, 7, 1371-1373.	9.4	65
34	Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. Biology of Blood and Marrow Transplantation, 2019, 25, 2002-2007.	2.0	64
35	Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood, 2015, 125, 3193-3201.	1.4	59
36	Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. Clinical Cancer Research, 2021, 27, 1058-1068.	7.0	53

#	Article	IF	Citations
37	CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CARâ€“refractory large B-cell lymphoma. Blood, 2021, 137, 2321-2325.	1.4	51
38	Clinical impact of H-Y alloimmunity. Immunologic Research, 2014, 58, 249-258.	2.9	50
39	Outcomes of Patients with Large B-cell Lymphoma Progressing after Axicabtagene Ciloleucel. Blood, 2021, 137, 1832-1835.	1.4	48
40	CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel. Blood, 2019, 134, 203-203.	1.4	48
41	Long-Term (â‰¥4 Year and â‰¥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). Blood, 2021, 138, 1764-1764.	1.4	48
42	Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. JCI Insight, 2019, 4, .	5.0	46
43	End of Phase 1 Results from Zuma-6: Axicabtagene Ciloleucel (Axi-Cel) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma. Blood, 2018, 132, 4192-4192.	1.4	46
44	Phase I Experience with a Bi-Specific CAR Targeting CD19 and CD22 in Adults with B-Cell Malignancies. Blood, 2018, 132, 490-490.	1.4	43
45	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances, 2021, 5, 4149-4155.	5.2	42
46	Experience with Axicabtagene Ciloleucel (Axi-cel) in Patients with Secondary CNS Involvement: Results from the US Lymphoma CAR T Consortium. Blood, 2019, 134, 763-763.	1.4	42
47	Phase I Trial Using CD19/CD22 Bispecific CAR T Cells in Pediatric and Adult Acute Lymphoblastic Leukemia (ALL). Blood, 2019, 134, 744-744.	1.4	42
48	Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica, 2015, 100, 1477-1485.	3.5	41
49	A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies. Blood, 2011, 118, 4070-4078.	1.4	40
50	Phase 1 Study of CD19/CD22 Bispecific Chimeric Antigen Receptor (CAR) Therapy in Children and Young Adults with B Cell Acute Lymphoblastic Leukemia (ALL). Blood, 2018, 132, 898-898.	1.4	40
51	ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 746-754.	2.0	37
52	Allogeneic T cells impair engraftment and hematopoiesis after stem cell transplantation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14721-14726.	7.1	33
53	Hâ€“Y antigen-binding B cells develop in male recipients of female hematopoietic cells and associate with chronic graft vs. host disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3005-3010.	7.1	30
54	Antibodies specifically target AML antigen NuSAP1 after allogeneic bone marrow transplantation. Blood, 2010, 115, 2077-2087.	1.4	29

#	Article	IF	Citations
55	Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 2021, 5, 4465-4475.	5.2	28
56	CD58 Aberrations Limit Durable Responses to CD19 CAR in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel but Can be Overcome through Novel CAR Engineering. Blood, 2020, 136, 53-54.	1.4	28
57	Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy. Leukemia and Lymphoma, 2019, 60, 503-506.	1.3	26
58	Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial. Journal of Experimental Medicine, 2020, 217, .	8.5	26
59	Nonmyeloablative allogeneic transplantation achieves clinical and molecular remission in cutaneous T-cell lymphoma. Blood Advances, 2020, 4, 4474-4482.	5.2	25
60	Therapeutic benefits targeting B-cells in chronic graft-versus-host disease. International Journal of Hematology, 2015, 101, 438-451.	1.6	22
61	Red blood cell transfusions are associated with <scp>HLA</scp> class I but not Hâ€Y alloantibodies in children with sickle cell disease. British Journal of Haematology, 2015, 170, 247-256.	2.5	21
62	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood, 2019, 133, 94-99.	1.4	21
63	Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia. Blood Advances, 2021, 5, 3147-3151.	5.2	21
64	Combined CD4 T-Cell and Antibody Response to Human Minor Histocompatibility Antigen DBY After Allogeneic Stem-Cell Transplantation. Transplantation, 2011, 92, 359-365.	1.0	19
65	Total Lymphoid Irradiationâ€“Antithymocyte Globulin Conditioning and Allogeneic Transplantation for Patients with Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Biology of Blood and Marrow Transplantation, 2014, 20, 837-843.	2.0	18
66	A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial. Transplantation and Cellular Therapy, 2021, 27, 932.e1-932.e11.	1.2	18
67	KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 Study. Blood, 2019, 134, 754-754.	1.4	18
68	Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma. Blood, 2021, 138, 2-2.	1.4	16
69	Antiâ€“Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2018, 24, 373-380.	2.0	15
70	Non-Myeloablative Allogeneic Transplantation Resulting in Clinical and Molecular Remission with Low Non-Relapse Mortality (NRM) in Patients with Advanced Stage Mycosis Fungoides (MF) and SÃ©zary Syndrome (SS). Blood, 2014, 124, 2544-2544.	1.4	15
71	Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood, 2020, 135, 28-40.	1.4	14
72	Allotype Reagents Distinguish Donor and Recipient Antibodies after Hematopoietic Transplantation.. Blood, 2006, 108, 2906-2906.	1.4	14

#	Article	IF	Citations
73	Recombinant Antigen Microarrays for Serum/Plasma Antibody Detection. Methods in Molecular Biology, 2011, 723, 81-104.	0.9	13
74	Validation of the Hematopoietic Cell Transplantationâ€“Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1744-1748.	2.0	12
75	A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica, 2019, 104, e314-e317.	3.5	11
76	Target Antigen Downregulation and Other Mechanisms of Failure after Axicabtagene Ciloleucel (CAR19) Therapy. Blood, 2018, 132, 4656-4656.	1.4	11
77	Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. Blood, 2014, 124, 4697-4697.	1.4	11
78	Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report. Transplantation and Cellular Therapy, 2022, 28, 215.e1-215.e10.	1.2	11
79	A Reduced-Toxicity Regimen Is Associated with Durable Engraftment and Clinical Cure of Nonmalignant Genetic Diseases among Children Undergoing Blood and Marrow Transplantation with an HLA-Matched Related Donor. Biology of Blood and Marrow Transplantation, 2015, 21, 440-444.	2.0	10
80	Outcomes with Autologous or Allogeneic Stem Cell Transplantation in Patients with Plasma Cell Leukemia in the Era of Novel Agents. Biology of Blood and Marrow Transplantation, 2020, 26, e328-e332.	2.0	10
81	Targeting PI3KÎ´ function for amelioration of murine chronic graft-versus-host disease. American Journal of Transplantation, 2019, 19, 1820-1830.	4.7	9
82	Outcomes after delayed and second autologous stem cell transplant in patients with relapsed multiple myeloma. Bone Marrow Transplantation, 2021, 56, 2664-2671.	2.4	9
83	Complete Donor Chimerism Predicts Molecular Remission in High Risk CLL Following Nonmyeloablative Transplantation.. Blood, 2008, 112, 3283-3283.	1.4	9
84	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood, 2021, 138, 530-530.	1.4	9
85	Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, S140.	2.0	8
86	HLA-mismatched unrelated donor transplantation using TLI-ATG conditioning has a low risk of GVHD and potent antitumor activity. Blood Advances, 2017, 1, 1347-1357.	5.2	8
87	Outcomes with autologous stem cell transplant vs. non-transplant therapy in patients 70 years and older with multiple myeloma. Bone Marrow Transplantation, 2021, 56, 368-375.	2.4	8
88	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. Blood, 2019, 134, 4095-4095.	1.4	8
89	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). Blood, 2020, 136, 40-42.	1.4	8
90	Identification of Two CAR T-Cell Populations Associated with Complete Response or Progressive Disease in Adult Lymphoma Patients Treated with Axi-Cel. Blood, 2019, 134, 779-779.	1.4	6

#	Article	IF	Citations
91	One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma. Blood, 2020, 136, 20-22.	1.4	6
92	Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. Blood, 2014, 124, 1186-1186.	1.4	6
93	Severity of Cytokine Release Syndrome Influences Outcome After Axicabtagene Ciloleucel for Large B cell Lymphoma: Results from the US Lymphoma CAR-T Consortium. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 753-759.	0.4	6
94	Rituximab in hematopoietic cell transplantation. Expert Opinion on Biological Therapy, 2010, 10, 971-982.	3.1	5
95	Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. Haematologica, 2016, 101, e30-e33.	3.5	5
96	Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era. Transplantation and Cellular Therapy, 2021, 27, 590.e1-590.e8.	1.2	5
97	ZUMA-11: A Phase 1/2 Multicenter Study of Axicabtagene Ciloleucel (Axi-Cel) + Utomilumab Patients with Refractory Large B Cell Lymphoma. Blood, 2019, 134, 4084-4084.	1.4	5
98	Use of Backup Stem Cells for Stem Cell Boost and Second Transplant in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 405.e1-405.e6.	1.2	4
99	Orca-T, a Precision Treg-Engineered Donor Product, Prevents Acute Gvhd with Less Immunosuppression in an Early Multicenter Experience with Myeloablative HLA-Matched Transplants. Blood, 2020, 136, 47-48.	1.4	4
100	Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents. Blood, 2019, 134, 2022-2022.	1.4	4
101	CD22-CAR T-Cell Therapy Mediates High Durable Remission Rates in Adults with Large B-Cell Lymphoma Who Have Relapsed after CD19-CAR T-Cell Therapy. Blood, 2021, 138, 741-741.	1.4	4
102	Bleeding and Thrombosis Are Associated with Endothelial Dysfunction in CAR-T Cell Therapy and Are Increased in Patients Experiencing Neurologic Toxicity. Blood, 2020, 136, 32-33.	1.4	4
103	Molecular Imaging of Chimeric Antigen Receptor T Cells By ICOS-Immunopet. Blood, 2020, 136, 5-6.	1.4	3
104	Profiling T-Cell Receptor Diversity and Dynamics during Lymphoma Immunotherapy Using Cell-Free DNA (cfDNA). Blood, 2020, 136, 49-50.	1.4	3
105	Allogeneic Antibodies Identify GVL Targets CHAF1b and NuSAP1 in AML Patients.. Blood, 2007, 110, 168-168.	1.4	3
106	IgG Allotypes Reveal That Antimicrobial Humoral Immunity Persists after Reduced-Intensity Hematopoietic Cell Transplantation. Blood, 2008, 112, 349-349.	1.4	3
107	Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Host Conditioning with Total Lymphoid Irradiation and Anti-Thymocyte Globulin Confirm a Low Incidence of Graft Versus Host Disease (GVHD) and Retained Graft Anti-Tumor Activity.. Blood, 2006, 108, 603-603.	1.4	3
108	Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product. Blood, 2020, 136, 2-3.	1.4	3

#	Article	IF	Citations
109	Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia in the Modern Era. Transplantation and Cellular Therapy, 2022, , .	1.2	3
110	Impaired B Cell Clonotype Diversification After Allogeneic Hematopoietic Cell Transplantation Predicts Graft-Versus-Host Disease. Biology of Blood and Marrow Transplantation, 2013, 19, S148-S149.	2.0	2
111	A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S324.	2.0	2
112	Ibrutinib Treatment of Relapsed CLL Following Allogeneic Transplantation: Sustained Disease Response and Promising Donor Immune Modulation. Biology of Blood and Marrow Transplantation, 2015, 21, S307-S308.	2.0	2
113	High-throughput allogeneic antibody detection using protein microarrays. Journal of Immunological Methods, 2016, 432, 57-64.	1.4	2
114	Recurrent Status Epilepticus in the Setting of Chimeric Antigen Receptor (CAR)-T Cell Therapy. Neurohospitalist, The, 2022, 12, 194187442110009.	0.8	2
115	Ibrutinib for Chronic Pulmonary Graft-Versus-Host-Disease after Progression on Prior Therapy. Blood, 2019, 134, 4532-4532.	1.4	2
116	Monitoring Measurable Residual Disease Using Peripheral Blood in Acute Lymphoblastic Leukemia: Results of a Prospective, Observational Study. Blood, 2020, 136, 22-23.	1.4	2
117	Rituximab Therapy for Steroid-Refractory Chronic GVHD: Safety and Efficacy Analysis.. Blood, 2004, 104, 2251-2251.	1.4	2
118	Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study. Blood, 2021, 138, 3885-3885.	1.4	2
119	Orca-T Results in High Gvhd-Free and Relapse-Free Survival Following Myeloablative Conditioning for Hematological Malignancies: Results of a Single Center Phase 2 and a Multicenter Phase 1b Study. Blood, 2021, 138, 98-98.	1.4	2
120	Allogeneic hematopoietic cell transplant for normal karyotype AML: indirect evidence of selection for adverse molecular profile. Bone Marrow Transplantation, 2015, 50, 1004-1006.	2.4	1
121	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. , 0, , 897-913.		1
122	Cytokine Induced Killer (CIK) Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation.. Blood, 2006, 108, 412-412.	1.4	1
123	Rituximab Infusion Two Months after HCT Decreases Alloreactive B Cell Responses While Recipient Plasma Cells Persist.. Blood, 2008, 112, 2234-2234.	1.4	1
124	Donor-Derived CIK Cell Infusion As Consolidative Therapy after Non-Myeloablative Allogeneic Transplant in Patients with Myeloid Neoplasms. Blood, 2015, 126, 3232-3232.	1.4	1
125	NUTRITIONAL DEFICIENCY CONTRIBUTING TO REFRACTORY ERYTHRODERMA IN HEMATOPOETIC CELL TRANSPLANT PATIENTS: DISTINCTIVE CLINICAL AND HISTOPATHOLOGICAL FINDINGS. Journal of the American Academy of Dermatology, 2021, , .	1.2	0
126	The Y-Specific Gene PRY Is Expressed in Normal Blood Cells as Well as Leukemia Cells and Can Elicit a Specific Antibody Response in Male Recipients of Hematopoietic Stem Cells from Female Donors.. Blood, 2004, 104, 4976-4976.	1.4	0

#	Article	IF	Citations
127	Sirolimus and Tacrolimus as Graft-vs.-Host Disease Prophylaxis in Allogeneic Stem Cell Transplantation: The Dana-Farber Cancer Institute Experience.. Blood, 2004, 104, 1227-1227.	1.4	0
128	Allogeneic B Cell Response to H-Y Minor Histocompatibility Antigens after Donor Lymphocyte Infusion Correlates with Disease Response.. Blood, 2004, 104, 296-296.	1.4	0
129	Prevention of Acute GVHD with Sirolimus Does Not Abrogate the Risk of Chronic GVHD.. Blood, 2004, 104, 3317-3317.	1.4	0
130	Donor T Cells from B Cell Deficient Mice Inhibit B Cell Development in Normal Recipients after Hematopoietic Cell Transplantation.. Blood, 2007, 110, 3265-3265.	1.4	0
131	Comparison of Three Minor-Mismatched Mouse Models of Chronic Graft Versus Host Disease.. Blood, 2007, 110, 3237-3237.	1.4	0
132	Composition and Persistence of Donor Cell Infiltrates in Host Target Organs Instigate the Development of Chronic Graft-Versus-Host Disease. Blood, 2008, 112, 3523-3523.	1.4	0
133	Long-Term Outcomes of Myeloablative Conditioning and Matched-Related Donor Hematopoietic Cell Transplantation for Patients with High-Risk and Advanced-Stage Hematolymphoid Malignancies. Blood, 2008, 112, 4383-4383.	1.4	0
134	Identification of a Homeobox-Like Protein Immune Response in Bone Marrow Transplant Patients. Blood, 2008, 112, 4856-4856.	1.4	0
135	Post Transplant Allogeneic Antibody Responses Form against Annexin 8. Blood, 2008, 112, 4605-4605.	1.4	0
136	Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation. Blood, 2008, 112, 4348-4348.	1.4	0
137	Phase I/II Trial of a Novel Gemcitabine and Vinorelbine-Containing Conditioning Regimen in Autologous Hemotopoietic Cell Transplantation for High-Risk Recurrent and Refractory Hodgkin Lymphoma.. Blood, 2008, 112, 2194-2194.	1.4	0
138	Modeling Chronic Graft-Versus-Host-Disease: A New MHC-Matched Model of Late-Onset Scleroderma After Low-Dose Conditioning and Hematopoietic Cell Transplantation That Affects Only Male Recipients of Female Grafts.. Blood, 2009, 114, 3560-3560.	1.4	0
139	A Dose Escalation Trial of Imatinib for Steroid Dependent Chronic Graft-Versus-Host Disease with Anti-PDGFRA Antibody Analysis.. Blood, 2009, 114, 3304-3304.	1.4	0
140	High-Throughput VDJ Sequencing Is Superior to Quantitative PCR and Flow Cytometry for the Quantification of Minimal Residual Disease In Chronic Lymphocytic Leukemia After Hematopoietic Cell Transplantation.. Blood, 2010, 116, 1290-1290.	1.4	0
141	Chronic Graft-Versus-Host Disease Responds to Imatinib and Pre Transplant/Donor Anti-PDGFRA Antibodies Predict for Chronic Graft-Versus-Host Disease Development. Blood, 2010, 116, 2320-2320.	1.4	0
142	Protein Microarrays Identify Elevated Allogeneic Antibodies In Association with Extensive Chronic Graft Versus Host Disease. Blood, 2010, 116, 2344-2344.	1.4	0
143	A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. Blood, 2011, 118, 1986-1986.	1.4	0
144	Non-Myeloablative Conditioning with Total Lymphoid Irradiation and ATG and Allogeneic Transplantation for Patients with Myelodysplastic Syndrome, Therapy-Related Myeloid Neoplasms, and Myeloproliferative Neoplasms.. Blood, 2012, 120, 3087-3087.	1.4	0

#	Article	IF	Citations
145	The Expansion of Gastrointestinal-associated Î±Î² T Cell Clones in Peripheral Blood Over Time Is a Disease Feature of Severe Acute Graft-Versus-Host Disease. Blood, 2012, 120, 228-228.	1.4	0
146	Risks and Benefits of Sex-Mismatched Hematopoietic Cell Transplantation Differ By Conditioning Intensity. Blood, 2014, 124, 2537-2537.	1.4	0
147	Prediction of Early Onset Cytokine Release Syndrome and Neurologic Events after Axicabtagene Ciloleucel in Large B-Cell Lymphoma Based on Machine Learning Algorithms. Blood, 2021, 138, 2833-2833.	1.4	0
148	Long-Term Outcomes of Patients with Peripheral T-Cell Lymphoma after Autologous Hematopoietic Cell Transplantation. Blood, 2020, 136, 33-34.	1.4	0
149	Survival Following Post-HCT Relapse in Adult Acute Lymphoblastic Leukemia Has Improved in the Era of Novel Immunotherapies: A Single Institution Analysis. Blood, 2020, 136, 48-49.	1.4	0
150	Outcomes after Autologous Stem Cell Transplant in Patients with Relapsed Multiple Myeloma. Blood, 2020, 136, 11-12.	1.4	0
151	Outcomes after Second Allogeneic Transplantation and Donor Lymphocyte Infusion for Relapse after a First Allogeneic Transplant. Blood, 2020, 136, 22-23.	1.4	0